NONMEM Users Network Archive

Hosted by Cognigen

IMI 2009: Drug/Disease Modelling; Open Information Day: 17th Nov 2009, Brussels

From: Harnisch, Lutz O <Lutz.O.Harnisch>
Date: Thu, 22 Oct 2009 11:57:20 +0100

Drug/Disease Modelling: Library & Framework (DDMLF): IMI 2009 Call Topic

The Innovative Medicines Initiative (IMI) is a unique pan-European
public-private partnership aiming to foster collaboration between large
and small biopharmaceutical and healthcare companies, regulators,
academia and patients aimed at promoting pre-competitive pharmaceutical
research and development. An essential goal of the IMI initiative is the
improvement of knowledge management.

Significant gaps and inconsistencies exist in knowledge integration
across the various phases of pharmaceutical development. This is largely
attributable to the inherent complexity associated with assimilating
such disparate information, and hinders efficiency and innovation.

Modelling and Simulation (M&S) is a discipline growing in importance
across all stages of pharmaceutical development, optimising tasks such
as target feasibility analyses, characterisation of drug/disease
properties, and prediction of clinical trials and integrating
information to allow informed decision-making in a quantitative context.
However, M&S technologies build on many data sources, formats and tools
either proprietary or incompatible with one another. This impedes the
ability of stakeholders (industry, academia and regulatory authorities)
to effectively leverage and share knowledge about drug, disease, placebo
and trial design properties, and ultimately impairs the evaluation of
efficacy and safety of new medicines.

With a view to addressing this, a call topic proposing the development
of a Drug and Disease Modelling Library and Framework has been included
as part of the Knowledge Management pillar of the 2009 IMI Calls.
Briefly, this topic proposes the development of the following:

* a public and freely available Library for drug/disease models,
to streamline the re-use and sharing of existing pharmacometric,
statistical and systems biology models and code,

* a software Framework to facilitate exchangeability and

* a set of common standards and languages describing
pharmacometric and systems biology data and models,

* and a set of disease prototypes across various disease areas,
serving as Proofs of Concept

When working in concert, these will provide the necessary infrastructure
for integration and sharing of knowledge in a quantitative drug
development context.

Full details of the call topic are provided from the IMI website at Details of the rules for
participation, and the call process, are at

Funding for the project, will be provided by IMI (projected to be EUR 9
million for a duration of 5 years) and matched by an equal amount
provided through the EFPIA Consortium as in-kind contributions
(expertise, employee time, and relevant data).

An IMI Open Information Day has been scheduled for November 17, 2009 in
Brussels in order to provide potential applicants from academic teams,
SMEs and other interested entities with practical information regarding
the preparation of expressions of interest in response to the new call.
All those interested are welcome to attend - an agenda and an online
registration form are available at

Hope to see you there!

Best regards
Lutz Harnisch and Justin Wilkins
for the EFPIA Steering Committee


Received on Thu Oct 22 2009 - 06:57:20 EDT

The NONMEM Users Network is maintained by ICON plc. Requests to subscribe to the network should be sent to:

Once subscribed, you may contribute to the discussion by emailing: